← Back to Search

Reduced-THC Cannabis for Cognitive Impairment from Cannabis Use (THC-YA Trial)

N/A

Waitlist Available

Led By Michael Sofis, PhD

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Between the ages of 21-25

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

THC-YA Trial Summary

This trial will test if switching to less potent THC products improves cognitive function in cannabis users aged 21-25.

Who is the study for?

This trial is for young adults aged 21-25 in San Francisco who use cannabis concentrates daily or almost daily, buying only from regulated stores. It's not for pregnant individuals or those regularly using drugs other than nicotine.Check my eligibility

What is being tested?

The study tests if switching to cannabis with lower THC potency (15% and 35% reductions) improves cognitive function in frequent users. It includes blood and urine tests to assess THC consumption and its effects on cognition.See study design

What are the potential side effects?

While the trial itself may not have direct side effects, using THC can lead to impaired memory, altered judgment, coordination issues, anxiety, paranoia, dizziness, dry mouth/eyes, increased appetite.

THC-YA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 21 and 25 years old.

THC-YA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Delayed Matching-to-Sample Score

Change in One-Touch Stockings of Cambridge score

Change in Paired Associates Learning score

+4 more

Secondary outcome measures

Baseline Urinary THC Excretion

Week 1 Urinary THC Excretion

Week 2 Urinary THC Excretion

+3 more

Other outcome measures

Baseline Adapted Cannabis Purchase Task

Baseline Participant Reported Affect

Baseline Participant Reported Cannabis Use

+21 more

THC-YA Trial Design

2Treatment groups

Experimental Treatment

Group I: 35% THC Potency Reduction GroupExperimental Treatment1 Intervention

Participants will be incentivized to use THC products that are at least 35% less potent than baseline

Group II: 15% THC Potency Reduction GroupExperimental Treatment1 Intervention

Participants will be incentivized to use THC products that are at least 15% less potent than baseline

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Cannabis Public Policy ConsultingUNKNOWN

University of California, San FranciscoLead Sponsor

2,507 Previous Clinical Trials

15,238,430 Total Patients Enrolled

1 Trials studying Cannabis Use

48 Patients Enrolled for Cannabis Use

Michael Sofis, PhDPrincipal InvestigatorCannabis Public Policy Consulting

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the minimum age qualification for participation in this experiment twenty-five years or younger?

"The requisites for being accepted into this study necessitate that the candidate is between 21 and 25 years old."

Answered by AI

Are there any eligibility requirements to participate in this clinical trial?

"To become part of this medical research, individuals should demonstrate prior cannabis usage and have to be between 21 and 25 years old. 110 people will partake in the trial overall."

Answered by AI

Are there any openings currently available for this investigation?

"The data on clinicaltrials.gov reports that this particular trial, which was first made available on January 1st 2024 and last updated October 4th 2023, is not presently enrolling participants. However, there are currently 775 other trials actively seeking patients to join them."

Answered by AI

What effect does this trial aim to accomplish?

"This trial will observe the Change in Paired Associates Learning score over a Baseline and 5 week period as its primary outcome. Secondary outcomes include Week 1, 2, and 3 Urinary THC Excretion which will be determined via Liquid Chromatography Mass Spectroscopy (LC/MS/MS). These results shall range between <5ng/mL to 5000 ng/mL; higher values indicating more THC present in urine sample compared to baseline levels."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults

2024. "Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06077292.

All > Cannabis